CIDRAP 16/09/13 CDC: Antibiotic-resistant bugs sicken 2 million a year The US Centers for Disease Control and Prevention (CDC) said today that antibiotic-resistant pathogens sicken 2 million Americans a year and listed the three most urgent threats as Clostridium difficile, carbapenem-resistant Enterobacteriaceae (CRE), and Neisseria gonorrhoeae. The agency's first all-encompassing report on antibiotic disease threats spans 114 pages and ranks the pathogens in part to spur a multipronged effort to prioritize and battle the problems. Antibiotic-resistant microorganisms play a role in 23,000 deaths each year, the CDC said. At a media briefing today, CDC Director Tom Frieden, MD, MPH, said the landmark report provides a snapshot of the antibiotic-resistant organisms that have the biggest impact on human health. He said the numbers are very conservative estimates that don't take into account infections that occur outside hospitals, such as nursing homes and dialysis centers. "The bottom line is stewardship," Frieden said. See also: Sep 16 CDC press release
JDLE 25/09/13 L’antibiorésistance tue chaque année 23.000 Américains. Les dangers de l'antibiorésistance précisés Les bactéries antibiorésistantes infectent chaque année au moins 2 millions d’Américains et en tuent 23.000, révèlent les centres de contrôle et de prévention des maladies (CDC) dans leur rapport 2013 sur le sujet. Outre son poids humain, l’antibiorésistance engendre un coût de santé annuel de 20 milliards de dollars (14,8 Md€), avec des pertes de productivité estimées à 35 Md$ (26 Md€). «Les antibiotiques constituent une ressource limitée, précieuse: plus nous les utilisons aujourd’hui, moins nous en aurons d’efficaces demain», rappelle Steve Solomon, directeur du bureau Antibiorésistance des CDC, dans un communiqué. De plus en plus répandue, l’antibiorésistance est en effet liée à un usage abusif des antibiotiques. Chez l’homme, auquel 50% des antibiotiques sont prescrits sans réelle nécessité médicale, mais aussi dans les élevages qui, aux Etats-Unis, consomment 74% de ces médicaments. Campylobacter et salmonelles, menaces «sérieuses»
CDC EID - Volume 21, Number 9—September 2015. Au sommaire: Emerging Infections Program as Surveillance for Antimicrobial Drug Resistance ; Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.K. Fridkin, A.A. Cleveland, I. See); Minnesota Department of Public Health, St. Paul, Minnesota, USA (R. Suggested citation for this article Abstract Across the United States, antimicrobial drug–resistant infections affect a diverse population, and effective interventions require concerted efforts across various public health and clinical programs. The 1992 Institute of Medicine report Emerging Infections: Microbial Threats to Health in the United States describes the ability of microbes to adapt, the development of antimicrobial drug resistance, and the importance of recognizing and monitoring emerging microbial threats to human health (1). EIP as an Antimicrobial Drug Resistance Surveillance System EIP is grounded in performing active population-based and laboratory-based surveillance. Examples of Antimicrobial Drug Resistance Surveillance and Research in EIP Dr. References
CDC EID – MAI 2014 – Au sommaire: Factors Associated with Antimicrobial Drug Use in Medicaid Programs Author affiliations: University of Pennsylvania, Philadelphia, Pennsylvania, USA Suggested citation for this article Abstract Using US Medicaid data, we found that 52% of adult Medicaid patients with acute respiratory tract infections filled prescriptions for antimicrobial drugs in 2007. Factors associated with lower likelihood of use were higher county-level availability of primary care physicians and state-level participation in a campaign for appropriate antimicrobial drug use. Antimicrobial drugs are not recommended for the treatment of acute respiratory tract infections (ARIs), such as colds, upper respiratory tract infections (URIs), and acute bronchitis (1,2). Inappropriate use of antimicrobial drugs in Medicaid programs is a potentially serious problem (4,5). We used the 2007 Medicaid Analytic Extract files for patients >21 years of age from 40 states linked with the Area Resource File. References Figure Figure. Tables Technical Appendix
CDC - Antimicrobial Resistance Threat Report 2013. Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content Get Email Updates To receive email updates about this page, enter your email address: CDCAntibiotic / Antimicrobial Resistance Antibiotic Resistance Threats in the United States, 2013 Recommend on Facebook Tweet This report, Antibiotic resistance threats in the United States, 2013 gives a first-ever snapshot of the burden and threats posed by the antibiotic-resistant germs having the most impact on human health. Each year in the United States, at least 2 million people become infected with bacteria that are resistant to antibiotics and at least 23,000 people die each year as a direct result of these infections. Antibiotic-resistant infections can happen anywhere. What's in the Report Foreword[page 5]( Microorganisms with a Threat Level of Urgent Related Links Top
NIH 07/04/14 NIH Funding Opportunity Focuses on Diagnostics for Hospital-Based Antibacterial-Resistant Infections - Awards to Total up to $12 Million in 2015 The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, recently announced a research funding opportunity to develop and/or produce diagnostics to quickly detect the key bacteria responsible for antibacterial-resistant infections in hospital settings. NIAID expects to fund 10-15 awards for a total of up to $12 million in 2015. The maximum length of each award is 5 years. Drug-resistant bacterial infections are a growing worldwide problem, causing significant illness, death and healthcare cost. Many of these infections are acquired in hospitals and other healthcare settings, where rapid and sensitive testing for specific types of bacteria are needed to enable physicians to determine the most effective treatments to improve individual patient outcomes and help curb bacterial resistance. Investigators from academic organizations are eligible to submit proposals, but must establish a partnership with an industrial organization.
CDC EID - Volume 20, Number 12—December 2014. Au sommaire: Effects of Knowledge, Attitudes, and Practices of Primary Care Providers on Antibiotic Selection, United States Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA Suggested citation for this article Abstract Appropriate selection of antibiotic drugs is critical to optimize treatment of infections and limit the spread of antibiotic resistance. Antibiotic prescribing guidelines establish standards of care, help focus efforts on quality improvement, and have been shown to improve patient outcomes (1–3). Published qualitative studies that have examined antibiotic selection among primary care providers (PCPs) are outdated and focus on non-US–based physicians; they do not include nurse practitioners or physician assistants, who together comprise >25% of the US primary care workforce (15–22). We conducted in-depth interviews by digitally recorded telephone calls, and transcribed the recordings to text to accurately and reliably assess PCP KAPs. Thirty-six PCPs were selected for the study. Interviews were conducted during May 2013. Antibiotic Selection Acknowledgment
AASV 27/12/16 FDA Annual Summary Report on Antimicrobials Sold or Distributed in 2015 for Use in Food-Producing Animals December 27, 2016 — The U.S. Food and Drug Administration today published its annual report summarizing sales and distribution data for all antimicrobial drugs approved for use in food-producing animals. The report shows that sales and distribution of all antimicrobials increased 1 percent from 2014 through 2015, tying for the lowest annual increase since 2009. The percentage of those antimicrobials that are considered medically important in human medicine increased by 2 percent from 2014 through 2015. [Source: FDA CVM, December 22, 2016] Section 105 of the Animal Drug User Fee Amendments of 2008 (ADUFA 105) requires antimicrobial drug sponsors to report to FDA on an annual basis the amount of antimicrobial drugs they sell or distribute for use in food-producing animals. Please see the 2015 Summary Report on Antimicrobials Sold or Distributed for Use in Food-Producing Animals for more information. Additional Information
2009 - The Interagency Task Force on Antimicrobial Resistance and A Public Health Action Plan to Combat Antimicrobial Resi 2011 Annual Report Progress Report: 2011 Progress Towards Implementation of: A Public Health Action Plan to Combat Antimicrobial Resistance [PDF - 69 pages] Top 2009-2010 Annual Report Progress Report: 2009-2010 Progress Towards Implementation Of: Draft Document A Public Health Action Plan To Combat Antimicrobial Resistance [PDF - 346 KB] 2008 Annual Report Progress Report: Implementation of a Public Health Action Plan to Combat Antimicrobal Resistance. 2007 Annual Report (Released June 2008) 2007 Annual Report Download the complete 2007 Annual Report [PDF - 844 KB] 2006 Annual Report (Released June 2007) Listed below are historical, archived information. 2005 Annual Report (Released June 2006) 2004 Annual Report (Released June 2005) 2003 Annual Report (Released June 2004) 2002 Annual Report 2001 Annual Report (Released June 2002)
CDC 03/08/17 Antibiotic Resistance Lab Network About the AR Lab Network Established in 2016, CDC’s Antibiotic Resistance Laboratory Network (AR Lab Network) supports nationwide lab capacity to rapidly detect antibiotic resistance in healthcare, food, and the community, and inform local responses to prevent spread and protect people. The AR Lab Network includes seven regional labs, the National Tuberculosis Molecular Surveillance Center (National TB Center), and labs in 50 states, six cities, and Puerto Rico. As a whole, the network tracks changes in resistance and helps identify and respond to outbreaks faster. AR Lab Network Regional Labs and the National TB Molecular Surveillance Center detect existing and emerging types of antibiotic resistance, track emerging resistance more effectively, and generate stronger data to protect people and combat future resistance threats. This ambitious approach transforms the nation’s laboratory landscape by establishing the much-needed infrastructure across the nation. How the AR Lab Network Works
Infect Dis Clin North Am. 2016 Jun;30(2):377-390. Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned.